Biohaven Pharmaceuticals Holding, which is developing treatments for migraine and neurological disorders, raised $168 million by offering 9.9 million shares at $17, above the range of $14 to $16. Biohaven Pharmaceuticals plans to list on the NYSE under the symbol BHVN. Morgan Stanley, Piper Jaffray and Barclays acted as lead managers on the deal.
